Ignite Creation Date:
2024-05-06 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 12:45 PM
Study NCT ID:
NCT03519178
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-26
First Post:
2018-02-22
Brief Title:
A Study of PF-06873600 in People With Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HR HER2- Metastatic Breast Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Triple Negative Breast Cancer Male Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Leuprolide acetate | View |
| Hormone Receptor HR Positive Breast Cancer | View |
| Estrogen receptor ER positive | View |
| Progesterone receptor PR positive | View |
| Cyclin-dependent kinase CDK | View |
| Human epidermal growth factor receptor 2 HER2 negative | View |
| Advanced breast cancer | View |
| Metastatic breast cancer MBC | View |
| Triple negative breast cancer TNBC | View |
| Epithelial ovarian cancer EOC | View |
| Fallopian tube cancer | View |
| Primary peritoneal cancer PPC | View |
| CDK46 inhibitor | View |
| Endocrine Therapy ET | View |
| Measurable disease | View |
| Luteinizing Hormone Releasing Hormone LHRH Agonist | View |
| Goserelin | View |